News

Cordex has signed an agreement with Clinical Trials International (CTI), regarding a license to develop and market Cordex’s drug candidate ATPotent. ATPotent is a novel ATP-based drug candidate

Cell Therapeutics (CTI) has reported pixantrone clinical studies, including follow-up data and subgroup analyses of high risk patients, from the phase-III Extend Pix 301 clinical trial of pixantrone

China Pharma has received official approval from China’ State Food and Drug Administration (SFDA) to enter phase-I and phase-II clinical trials, to test the efficacy of cholesterol-lowering drug,

Merck KGaA has initiated its global phase-III clinical study of the therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. Stimuvax is

Biogen has enrolled its first patient in phase III, randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of PEGylated interferon beta-1a (BIIB017) in patients with

Wyeth has exercised its option under the terms of its collaboration agreement with Trubion, to extend the research period for an additional one-year period through Dec. 22, 2010.

For the fiscal 2009, profit from continuing activities rose to GBP4.2 million from GBP2.8 million in the previous year. Earnings per share from continuing operations were 16.166 pence

Enzon has initiated the phase-II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers in US to patients diagnosed with metastatic

Neovacs plans to initiate a phase-II study of its TNF Kinoid, subject to regulatory consent, in rheumatoid arthritis patients who have failed treatment with at least one TNF